C Schroeder
Pulmonary Disease · Beverly Hills, CANPI 1386755346
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $245,250 of the $268,238 with a category attached, or 91.4%. GSK accounts for 97.7% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2022 at $100,317 and has fallen 98.8% since, to $1,203 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $571.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$262K
- Viiv Healthcare Company$2K
- AstraZeneca$1K
- AbbVie$560
- Johnson & Johnson$328
- Lilly USA, LLC$227
- plus $3K from 34 others
Across 39 payments — averaging $3684.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$73K
- GSK$70K
What the payments were for
- Consulting fees$4,2252%
- Speaking & faculty fees$245,25091%
- Travel & lodging$8,7273%
- Food & beverage$10,0234%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$135,732
- NUCALA$15,675
- ANORO$7,447
- ANORO ELLIPTA$1,200
- BREZTRI$239
How this compares
$268,238 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $43,047 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,412 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $22,569 |
| LinzessLinaclotide | 12 | $7,620 |
| TrintellixVortioxetine Hydrobromide | 11 | $6,144 |
| Levothyroxine Sodium | 72 | $3,496 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,384 |
| SynthroidLevothyroxine Sodium | 32 | $1,646 |
| PaxlovidNirmatrelvir/Ritonavir | 28 | $1,429 |
| Rosuvastatin Calcium | 51 | $1,149 |
| Bupropion XlBupropion Hcl | 12 | $1,001 |
| Estradiol | 17 | $893 |
| Liothyronine Sodium | 22 | $767 |
| ValacyclovirValacyclovir Hcl | 22 | $765 |
| Nebivolol Hcl | 20 | $753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $261,968 | $48,98170 claims |
| Lilly USA, LLCMounjaro | $227 | $43,04738 claims |
| AbbVieLinzess, Synthroid | $560 | $9,26544 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $57 | $6,14411 claims |
| AstraZenecaSymbicort | $1,040 | $3,38413 claims |
| PfizerPaxlovid | $47 | $1,42928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Beverly Hills
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.